You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model

    SBC: Cytex Therapeutics, Inc.            Topic: NIAMS

    AbstractThe treatment of large cartilage lesions is a difficult clinical problem for which there are few good solutionsLeft untreatedthese lesions tend to degenerate to chronic pain and osteoarthritisOAultimately requiring a total joint replacementFor patients suffering from knee OAandin particularunicompartmental OAunicondylar knee arthroplastyUKAis an available first line treatment option that p ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Receptors, Ligands, and Catalysts on Demand using Expanded Genetic Alphabets

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: 100

    ABSTRACTTechnology to deliveron demandmolecules that bind targets or catalyze reactions of choice has been a goal of chemistry foryearsEven todaytheory is inadequate to support de novo design of receptors having useful affinity or catalysts having useful turnoverThusmany have sought to create those catalysts on a DNA or RNAcollectivelyxNAusing the Darwinism to these biomolecules to evolveunder lab ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Microfluidic Nitric Oxide Sensor

    SBC: CLINICAL SENSORS, INC.            Topic: NIAID

    PROJECT SUMMARY Clinical Sensors has developed a manufacturable prototype microfluidic sensor for measuring nitric oxide in whole bloodThis STTR Phase II project aims to complete several key aims necessary to commercialize this deviceincluding a clinical study where NO levels will be evaluated clinically in sepsisSepsis is the leading cause of death in non cardiac intensive care unitsICUsEach year ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases

    SBC: Eyedesis Biosciences, LLC            Topic: N

    PROJECT SUMMARY ABSTRACT Persistent disease activity PDA in spite of anti vascular endothelial growth factor VEGF therapy remains a significant clinical unmet need for patients with neovascular age related macular degeneration NVAMD The purpose of this STTR Phase I grant application is to develop novel therapies that will be effective for the treatment of PDA associated with NVAMD The cu ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Lead Compound Discovery from Engineered Analogs of Occidiofungin

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    Project Summary Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have also revealed that occi ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a small peptide to control autoimmune inflammation in type diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Abstract Type Diabetes T D affects an ever growing population While this disease typically has been associated with juveniles the disease in adult populations is rapidly increasing The defining clinical component is insulin loss which occurs because of sustained inflammation in the islets At present there is no means to prevent or reverse insulin loss A major inflammatory pathway in T D ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Aminooxyacetic Acid Prodrugs for Colon Cancer Therapy

    SBC: CBS THERAPEUTICS, INC.            Topic: 102

    ABSTRACT Recent studies of the applicants support the role of the endogenous gaseous biological mediator hydrogen sulfide H S in colorectal cancer In specific the selective upregulation of cystathionine synthase CBS and the subsequent production of H S in colonic cancer cells serves as a pro survival factor by stimulating tumor cell bioenergetics ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Microparticulate mucosal vaccine for triple-negative breast cancer

    SBC: Kiromic BioPharma, Inc.            Topic: 103

    ABSTRACT Triple negative breast cancerTNBCis a molecular subtype of breast cancer that is negative for expression of estrogen and progesterone receptors and human epidermal growth factor receptorHERClinicallyit is characterized by aggressive behaviordistinct patterns of metastasisand high rates of recurrence and mortalitySince TNBC tumor cells lack the necessary receptorsthe disease does not respo ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    Project Summary Abstract Glioblastoma GBM is the most common primary brain tumor and one of the deadliest forms of cancer Standard surgery chemotherapy and radiation fail to eliminate the infiltrative invasive cancer cells Median survival remains only months Drugs that seek out the disseminated GBM cells behind the blood brain barrier will prevent the inevitable recurrence in patients ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Aspirin-PC for Chemoprevention of Colorectal Cancer

    SBC: PLx Opco Inc.            Topic: NCI

    ABSTRACT Colorectal cancerCRCis the third leading cause of cancer related deaths in the U SBased on numerous epidemiological studies and recent prospective clinical trialsthe use of daily aspirin is associated with a significant reduction in CRC incidencedeaths and metastatic spreadHoweverthe chronic use of this drug is limited due to the side effects of gastrointestinal bleeding ulceration in sus ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government